Linked Life Data

11803729

Source:http://linkedlifedata.com/resource/pubmed/id/11803729

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2002-1-23
pubmed:abstractText
Five studies have been conducted with the atypical anti-psychotic amisulpride (100-1200 mg/day) involving 1358 patients with acute exacerbations of schizophrenia; four studies were short-term (4-8 weeks), double-blind studies and one was a 12-month, open, randomized comparison. Amisulpride improved positive symptoms consistently, and changes were more pronounced than with haloperidol, flupenthixol and risperidone; amisulpride showed a more rapid onset of action compared to haloperidol, and improvement in negative symptoms was more effective than with any comparator. An optimum response was obtained with amisulpride doses 400-800 mg/day. The long-term study confirmed the usefulness of amisulpride for maintenance treatment in schizophrenia, with a clear advantage over haloperidol, leading to better functioning and quality of life. Amisulpride caused fewer neurological side-effects than conventional anti-psychotics and less weight gain than risperidone, both of which are crucial factors for long-term compliance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-0605
pubmed:author
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
451-66
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Clinical advantages of amisulpride in the treatment of acute schizophrenia.
pubmed:affiliation
Department of Psychiatry, St George's Hospital Medical School, London, UK. tburns@sghms.ac.uk
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't